Tecentriq 1 875 mg solution for injection

DRUG3 trials

Sponsors

Oslo University Hospital HF, Isala Klinieken Stichting, Universita' Degli Studi Di Torino

Conditions

CancerInflammatory bowel diseaseNon Small Cell Lung CancerOncologyRheumatic disease

Phase 2

Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

RecruitingCTIS2023-507894-16-00

Oslo University Hospital HFCancer

Start: 2021-04-01Target: 6000Updated: 2026-01-22

DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

Not yet recruitingCTIS2026-525268-16-00

Universita' Degli Studi Di TorinoNon Small Cell Lung Cancer

Target: 962Updated: 2026-10-19

Phase 4

Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)

Not yet recruitingCTIS2024-518878-14-01

Isala Klinieken StichtingInflammatory bowel disease, Oncology, Rheumatic disease

Target: 1261Updated: 2025-12-18